Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
Dang, N Ogura, M Castaigne, S Fayad, L Jerkeman, M Radford, John A Pezzutto, A Bondarenko, I Stewart, D Shnaidman, M
Dang, N
Ogura, M
Castaigne, S
Fayad, L
Jerkeman, M
Radford, John A
Pezzutto, A
Bondarenko, I
Stewart, D
Shnaidman, M
Citations
Altmetric:
Abstract
Description
Lymphoma Research Team
Date
2017-07-05
Publisher
Collections
Keywords
Type
Article
Citation
Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. 2017 Br J Haematol